Multiple Sclerosis

The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.

Latest News

man with mulitple sclerosis and walker | Image credit: chartphoto - stock.adobe.com
The Rise of Precision Monoclonal Antibodies in Treating MS

July 7th 2025

Advancements in B-cell therapies, including anti-CD20 and anti-CD19 monoclonal antibodies, enhance treatment efficacy and safety for multiple sclerosis and autoimmune diseases.

The MUSETTE trial did not meet its primary end point, suggesting a higher dose of IV ocrelizumab does not provide added benefits compared with the currently approved 600 mg dose. | Image credit: Chanintorn.v - stock.adobe.com
Higher-Dose Ocrelizumab Shows No Added Benefit vs Approved Dose in MS

April 9th 2025

MS wordcloud | Image Credit: © arloo-stock.adobe.com
5 Ongoing Clinical Trials Evaluating Treatment for MS

March 14th 2025

Kavita Nair Q&A - Maks_Lab - stock.adobe.com.jpeg
Coming Together to Ensure Neurological Treatment Access: Q&A With Kavita V. Nair, PhD

March 12th 2025

Ocrelizumab is approved as an IV infusion for relapsing and primary progressive forms of MS and as a subcutaneous injection, given twice a year. | Image credit: Trsakaoe - stock.adobe.com
Real-World Discontinuations of Ocrelizumab in MS Comparable to Pivotal Trials

January 9th 2025

Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain key insights into managing and understanding this condition.

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain valuable insights into managing and understanding this complex condition.
Continuing Medical Education
View All
July 8th 2025

The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of Early Intervention, Patient-Centered Care, and Disease-Modifying Therapies in Slowing Disease Progression

1.0 Credit / Neurology
July 8th 2025

Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis

1.0 Credit / Immunology, Neurology
July 8th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
July 8th 2025

Overview and Burden of Migraine

0.5 Credit / Neurology
July 8th 2025

The Role of the Pharmacist Migraine Management

0.5 Credit / Neurology
July 8th 2025

The Evolving Treatment Landscape of Migraine

0.5 Credit / Neurology
July 8th 2025

Leveraging Managed Care to Optimize Patient Outcomes: Integrating Novel Treatments in Schizophrenia

1.5 Credits / Neurology, Psychiatry
July 8th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Site Logo
January 19th 2019

Double-Blinded Extension of the RADIANCE Trial Demonstrates the Efficacy and Safety of Ozanimod in Patients With Multiple Sclerosis

Cohen JA, Comi G, Arnold DL, et al RADIANCE Trial Investigators. Efficacy safety of ozanimod in multiple sclerosis: dose-blinded extension of a randomized phase II study [published online July 25, 2018]. Mult Scler. 2018:1352458518789884. doi: 10.1177/1352458518789884.
Site Logo
January 19th 2019

Interferon-beta Versus Glatiramer Acetate as Initial Treatment for Multiple Sclerosis: Long-term Follow-up

Healy BC, Glanz BI, Zurawski JD, Mazzola M, Chitnis T, Weiner HL. Long-term follow-up for multiple sclerosis patients initially treated with interferon-beta, glatiramer acetate. J Neurol Sci. 2018, 394:127-131. doi: 10.1016/j.jns.2018.09.020.
Earlier Treatment With Disease-Modifying Therapies Decreases Risk of MS Progression
January 18th 2019

Earlier Treatment With Disease-Modifying Therapies Decreases Risk of MS Progression

Laura Joszt, MA
Treating patients with relapsing-remitting multiple sclerosis (MS) early with disease-modifying treatment can reduce the risk of conversion to secondary progressive MS.
Could Coffee and Caffeine Treat Fatigue in Patients With MS?
January 12th 2019

Could Coffee and Caffeine Treat Fatigue in Patients With MS?

Samantha DiGrande
Researchers hypothesized that because coffee and caffeine showed a beneficial effect on daytime tiredness in Parkinson disease, a similar positive effect might be assumed in multiple sclerosis (MS). Investigators compiled a systematic review focused on summarizing the possible effects of coffee and caffeine in MS.
Ocrelizumab Reduces Progression of Upper Extremity Impairment in Primary Progressive MS
January 8th 2019

Ocrelizumab Reduces Progression of Upper Extremity Impairment in Primary Progressive MS

Laura Joszt, MA
For patients with multiple sclerosis (MS), upper extremity (UE) impairment is not uncommon, and patients with primary progressive MS tend to have a higher prevalence of UE dysfunction and greater impairment.
Stem Cell Transplant Effective Therapy in Patients With RRMS
January 5th 2019

Stem Cell Transplant Effective Therapy in Patients With RRMS

Samantha DiGrande
A recent prospective phase 2 study sought to investigate autologous hematopoietic stem cell transplantation as a therapeutic intervention in multiple sclerosis (MS).
Perceptions of Patients With MS and Caregivers on Daily Activity Performance
January 3rd 2019

Perceptions of Patients With MS and Caregivers on Daily Activity Performance

Laura Joszt, MA
An evaluation of cognitive function measurements, performance in daily activities, and the perception of cognitive functions in patients with multiple sclerosis (MS) found caregiver perceptions more closely correlate with the test measurements than patient perceptions.
Genetic Risk Variant Tied to Type of CNS Cell Increases Risk of MS, Study Says
December 29th 2018

Genetic Risk Variant Tied to Type of CNS Cell Increases Risk of MS, Study Says

David Bai, PharmD
A genetic risk variant, rs7665090G, located near NFKB1, on astrocytes enhances the accessibility of the central nervous system (CNS) to peripheral immune cells, escalating the risk of autoimmune inflammation and multiple sclerosis (MS), according to the results of a recent study.
Switching Patients With MS Who Are Stable on Interferon β Has Suboptimal Outcomes
December 29th 2018

Switching Patients With MS Who Are Stable on Interferon β Has Suboptimal Outcomes

AJMC Staff
Patients with multiple sclerosis (MS) who are stable on an interferon β (INFβ) should remain on that therapy rather than switching to another INFβ, according to a study in ClinicoEconomics and Outcomes Research.
Researchers Identify New, Overlooked Target to Treat Multiple Sclerosis
December 27th 2018

Researchers Identify New, Overlooked Target to Treat Multiple Sclerosis

Laura Joszt, MA
Mature oligodendrocytes have been overlooked in the past as a way to treat multiple sclerosis, but a new study has found they might be able to help with remyelinating axons the same as new oligodendrocytes.
Food Allergies Associated With More Relapses in Patients With MS
December 21st 2018

Food Allergies Associated With More Relapses in Patients With MS

Laura Joszt, MA
Patients with multiple sclerosis (MS) who also have food allergies have more relapses than patients with no known food allergy, according to a new study published in the Journal of Neurology, Neurosurgery & Psychiatry.
FDA Warns of Rare Risks of MS Drug Alemtuzumab
December 20th 2018

FDA Warns of Rare Risks of MS Drug Alemtuzumab

Jaime Rosenberg
The FDA has issued a warning that rare but serious cases of stroke and tears in the lining of arteries in the head and neck have occurred in patients with multiple sclerosis (MS) who received treatment with alemtuzumab (Lemtrada).
CDC Launching Surveillance System to Study Multiple Sclerosis, Other Neurological Conditions
December 14th 2018

CDC Launching Surveillance System to Study Multiple Sclerosis, Other Neurological Conditions

Jaime Rosenberg
With $5 million appropriated from Congress, CDC is launching a National Neurological Conditions and Surveillance System to help increase understanding of neurological disorders and to further support neurologic research, starting with multiple sclerosis and Parkinson disease.
Some Lifestyle Factors Positively Impact Depression in People With Multiple Sclerosis
December 9th 2018

Some Lifestyle Factors Positively Impact Depression in People With Multiple Sclerosis

Laura Joszt, MA
Lifestyle factors like exercise, meditation, and alcohol use were inversely associated with depression risk, while smoking significantly predicted depression.
International Consensus on Timely Care for Multiple Sclerosis
December 7th 2018

International Consensus on Timely Care for Multiple Sclerosis

David Bai, PharmD
Multiple sclerosis (MS) is a progressive neurological disease that requires timely management, and a panel of neurologists has developed an internationally applicable standard of care for timely management in patients with MS.
Patients Who Stop Taking Gilenya May Experience Worsening of Multiple Sclerosis
December 4th 2018

Patients Who Stop Taking Gilenya May Experience Worsening of Multiple Sclerosis

Laura Joszt, MA
The FDA has issued a safety warning that patients who stopped taking Gilenya experienced worsening of multiple sclerosis, compared with before treatment started or during treatment, in rare cases.
Analysis Finds Rising Pregnancy Rates Among Women With Multiple Sclerosis
October 11th 2018

Analysis Finds Rising Pregnancy Rates Among Women With Multiple Sclerosis

David Bai, PharmD
A retrospective study by Houtchens et al on annual pregnancy rates from 2006 to 2014 reveals that US women with multiple sclerosis (MS) had increased pregnancy rates as compared to women without MS.
Top 5 AJMC® Articles of September 2018
September 30th 2018

Top 5 AJMC® Articles of September 2018

Here are the top 5 articles for the month of September.
Sex Hormones May Play an Important Role in Multiple Sclerosis Prevalence and Development
September 29th 2018

Sex Hormones May Play an Important Role in Multiple Sclerosis Prevalence and Development

David Bai, PharmD
In a review of sex hormones and their role in the development of multiple sclerosis (MS), Ysrraelit and Correale compiled multiple references to provide clinical details regarding hormones and their respective immunological mechanisms.
Natalizumab Improves Cognitive Function in Patients With MS
September 26th 2018

Natalizumab Improves Cognitive Function in Patients With MS

Jaime Rosenberg
For patients with multiple sclerosis (MS) being treated with natalizumab, cognitive function improved from baseline to 1 year and improved significantly across all domains from baseline to 2 years.
Researchers Tout Behavioral Science to Increase Physical Activity in Patients With MS
September 21st 2018

Researchers Tout Behavioral Science to Increase Physical Activity in Patients With MS

Jaime Rosenberg
Noting a disconnect between evidence of benefit and uptake of exercise in patients with multiple sclerosis (MS), researchers offer behavioral science, specifically Social Cognitive Theory, as an approach to increasing participation.
MS-SMART: First Multiarm Efficacy Trial in Progressive MS
September 20th 2018

MS-SMART: First Multiarm Efficacy Trial in Progressive MS

David Bai
The Multiple Sclerosis-Secondary Progressive Multi-Arm Randomization Trial (MS-SMART) is the first multiarm trial designed specifically to address the unmet need for further identification of neuroprotective drugs in secondary progressive multiple sclerosis.
B Cell–Mediated T Cell Proliferation Important for MS Pathogenesis
September 15th 2018

B Cell–Mediated T Cell Proliferation Important for MS Pathogenesis

David Bai
A recent study has discovered that B cells mediate spontaneous T cell proliferation through the HLA-DR15 haplotype, and this interaction between T cells and B cells may serve as a key factor in understanding the pathogenesis of multiple sclerosis (MS).
High Disability Levels in MS Associated With Higher Costs, Lower Quality of Life
September 12th 2018

High Disability Levels in MS Associated With Higher Costs, Lower Quality of Life

Jaime Rosenberg
As levels of disability increased among patients with multiple sclerosis (MS), cost of illness increased and health-related quality of life decreased.
Cerebral White Matter Demyelination Not a Hallmark of Myelocortical MS
September 7th 2018

Cerebral White Matter Demyelination Not a Hallmark of Myelocortical MS

David Bai
Findings from a retrospective study comparing typical and myelocortical multiple sclerosis (MS) identified major pathological differences between the 2 MS subtypes and determined that demyelination and neuronal degeneration are independent processes.
Researchers Identify New Subtype of Multiple Sclerosis
September 5th 2018

Researchers Identify New Subtype of Multiple Sclerosis

Jaime Rosenberg
New study findings have identified a subtype of multiple sclerosis—myelocortical multiple sclerosis—that has neuronal loss but no demyelination of the brain’s white matter, indicating that demyelination and neuronal degeneration occur independently.
Human–Machine Hybrid Predictions Led to Better Prognoses of MS, Study Finds
August 31st 2018

Human–Machine Hybrid Predictions Led to Better Prognoses of MS, Study Finds

Alison Rodriguez
Researchers evaluating the different methods used to predict the progression of multiple sclerosis (MS) found that human–machine hybrid predictions led to better prognoses than did machine learning algorithms or groups of humans alone.
Extracellular Vesicles an Important Biomarker for Monitoring Response to MS Treatment
August 30th 2018

Extracellular Vesicles an Important Biomarker for Monitoring Response to MS Treatment

David Bai
A study has shed new light into the role of extracellular vesicles (EVs) in multiple sclerosis (MS) and how fingolimod, an immunomodulator drug, affects EVs.
MS Associated With Poor Sleep Quality, Anxiety, Depression
August 29th 2018

MS Associated With Poor Sleep Quality, Anxiety, Depression

Jaime Rosenberg
More than half of patients with multiple sclerosis (MS) in the BETASLEEP study indicated poor sleep quality, which was linked to fatigue and reduced quality of life over time.
Mapping the Nervous System May Shed Light on the Origin of Different Neurological Diseases
August 24th 2018

Mapping the Nervous System May Shed Light on the Origin of Different Neurological Diseases

Alison Rodriguez
Researchers recently developed a systematic map of the cell types that make up the mouse nervous system which has the ability to reveal new information about the origin of neurological diseases, and may lead to a detailed map of the human brain.
<1
...
111213141516171819
...
21>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo